Vanda Pharmaceuticals Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on February 25, 2021, reporting events that occurred on February 24, 2021. The filing details the Compensation Committee's decisions regarding executive compensation, including 2020 annual bonuses, 2021 base salaries, bonus targets, and new equity grants for named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures.
- 2020 Annual Bonuses Paid: Total of $1,256,687 awarded to four named executive officers.
- 2021 Base Salaries Approved: Total annual base salary of $2,045,000 for the four named executive officers.
- 2021 Bonus Targets: Ranging from 45% to 80% of base salary.
- Equity Grants: Options and Restricted Stock Units (RSUs) granted at an exercise price of $20.28 per share.
Material Changes
The filing reports the establishment of 2021 compensation structures and the payout of 2020 performance bonuses. There are no reported material changes to the company's financial position, operations, or capital structure in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies. It notes that executive compensation was benchmarked against a peer group analysis conducted by Willis Towers Watson.
Key Facts for Investor Verification
- CEO Compensation: Mihael Polymeropoulos received a $656,687 bonus for 2020, a $769,000 base salary for 2021, an 80% bonus target, 275,000 stock options, and 115,000 RSUs.
- Equity Vesting: Options vest 25% on February 24, 2022, with the remainder monthly over 36 months. RSUs vest in four equal annual installments starting March 1, 2022.
- Stock Price Reference: The exercise price for new options is set at $20.28, the closing price on February 24, 2021.
- Peer Group Benchmarking: Compensation decisions were informed by an external consultant's peer group analysis.